» Articles » PMID: 35997457

Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling

Overview
Date 2022 Aug 23
PMID 35997457
Authors
Affiliations
Soon will be listed here.
Abstract

The present research aimed to characterize soft tissue implants that were prepared with the use of crosslinked hyaluronic acid (HA) using two different crosslinkers and multiple reagent concentrations, alone or in combination with fibrin. The effect of the implants was evaluated in an in vivo mouse model, after 4 weeks in one group and after 12 weeks in the other. The explants were compared using analytical methods, evaluating microscopic images, and a histology analysis. The kinetics of the degradation and remodeling of explants were found to be greatly dependent on the concentration and type of crosslinker; generally, divinyl sulfone (DVS) resists degradation more effectively compared to butanediol diglycidyl ether (BDDE). The presence of fibrin enhances the formation of blood vessels, and the infiltration of cells and extracellular matrix. In summary, if the aim is to create a soft tissue implant with easier degradation of the HA content, then the use of 2-5% BDDE is found to be optimal. For a longer degradation time, 5% DVS is the more suitable crosslinker. The use of fibrin was found to support the biological process of remodeling, while keeping the advances of HA in void filling, enabling the parallel degradation and remodeling processes.

Citing Articles

Are We Overlooking Harms of BDDE-Cross-Linked Dermal Fillers? A Scoping Review.

Wojtkiewicz M, Stachura A, Roszkowski B, Winiarska N, Kazimierska K, Stachura K Aesthetic Plast Surg. 2024; 48(23):5147-5154.

PMID: 39107664 PMC: 11739315. DOI: 10.1007/s00266-024-04262-0.


Water-Insoluble, Thermostable, Crosslinked Gelatin Matrix for Soft Tissue Implant Development.

Varga V, Smeller L, Vardai R, Kocsis B, Zsoldos I, Cruciani S Int J Mol Sci. 2024; 25(8).

PMID: 38673921 PMC: 11050114. DOI: 10.3390/ijms25084336.


Injectable fillers: current status, physicochemical properties, function mechanism, and perspectives.

Guo J, Fang W, Wang F RSC Adv. 2023; 13(34):23841-23858.

PMID: 37577103 PMC: 10413051. DOI: 10.1039/d3ra04321e.


Editorial: Biomaterial applications in soft tissue engineering and replacement.

Hornyak I, Jedlovszky-Hajdu A, Kehr S Front Bioeng Biotechnol. 2023; 11:1227021.

PMID: 37324428 PMC: 10262844. DOI: 10.3389/fbioe.2023.1227021.


Polymer Gels: Classification and Recent Developments in Biomedical Applications.

Chelu M, Musuc A Gels. 2023; 9(2).

PMID: 36826331 PMC: 9956074. DOI: 10.3390/gels9020161.

References
1.
Hinsenkamp A, Benyo Z, Hornyak I . Overview of Tissue Engineering Patent Strategies and Patents from 2010 to 2020, Including Outcomes. Tissue Eng Part B Rev. 2021; 28(3):626-632. DOI: 10.1089/ten.TEB.2021.0045. View

2.
Salwowska N, Bebenek K, Zadlo D, Wcislo-Dziadecka D . Physiochemical properties and application of hyaluronic acid: a systematic review. J Cosmet Dermatol. 2016; 15(4):520-526. DOI: 10.1111/jocd.12237. View

3.
Hinsenkamp A, Kun K, Gajnut F, Majer A, Lacza Z, Hornyak I . Cell Attachment Capacity and Compounds of Fibrin Membranes Isolated from Fresh Frozen Plasma and Cryoprecipitate. Membranes (Basel). 2021; 11(10). PMC: 8541203. DOI: 10.3390/membranes11100783. View

4.
Oh E, Kang S, Kim B, Jiang G, Cho I, Hahn S . Control of the molecular degradation of hyaluronic acid hydrogels for tissue augmentation. J Biomed Mater Res A. 2007; 86(3):685-93. DOI: 10.1002/jbm.a.31681. View

5.
Stern R, Asari A, Sugahara K . Hyaluronan fragments: an information-rich system. Eur J Cell Biol. 2006; 85(8):699-715. DOI: 10.1016/j.ejcb.2006.05.009. View